Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/15/2021 06/16/2021 06/17/2021 06/18/2021 06/21/2021 Date
201.59(c) 197.84(c) 202.47(c) 199.19(c) 206.22 Last
6 786 260 7 264 747 4 955 160 6 663 813 3 617 543 Volume
-2.81% -1.86% +2.34% -1.62% +3.53% Change
More quotes
Financials (USD)
Sales 2021 18 664 M - -
Net income 2021 10 397 M - -
Net cash position 2021 11 520 M - -
P/E ratio 2021 8,08x
Yield 2021 -
Sales 2022 15 893 M - -
Net income 2022 7 759 M - -
Net cash position 2022 20 906 M - -
P/E ratio 2022 11,2x
Yield 2022 -
Capitalization 79 980 M 79 980 M -
EV / Sales 2021 3,67x
EV / Sales 2022 3,72x
Nbr of Employees 1 300
Free-Float 90,3%
More Financials
Company
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for infectious, autoimmune and cardiovascular diseases. Turnover per type of income can be broken down as follows: - Collaboration revenue (79.8%); - Grant revenue (20.2%). At the end of 2019, the group possessed a portfolio of 6 development candidates in clinical studies, with three in phase II and... 
Read more
More about the company
Ratings of Moderna, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about MODERNA, INC.
11:17aMODERNA  : Ontario reports 270 COVID-19 cases, three deaths from the virus on Mo..
AQ
10:43aBionity - Mix-and-match vaccines generate a particularly strong immune respon..
AQ
10:41aMODERNA  : Reaffirms Commitment to Job Creation in Massachusetts
AQ
09:01aMODERNA  : set to expand Covid-19 vaccine production
AQ
07:27aTHE LATEST : Indonesia records its largest jump in infections
AQ
07:21aMODERNA PLANS TO EXPAND COVID-19 VAC : Wsj
RE
07:04aMODERNA  : Plans To Expand Production To Make COVID-19 Vaccine Boosters, Supply ..
RE
07:04aModerna plans to expand production to make covid-19 vaccine boosters, supply ..
RE
12:24aSwitzerland To Begin COVID-19 Vaccinations For Ages 12 To 15
MT
06/20PFIZER  : Ontario reports 318 new cases of COVID-19 as province prepares for Pfi..
AQ
06/20Philippines seals biggest COVID-19 vaccine order yet, for 40 mln Pfizer doses
RE
06/20Philippines seals deal for 40 mln Pfizer/BioNTech COVID-19 doses
RE
06/19MODERNA  : U.S. administers more than 317 mln doses of COVID-19 vaccines - CDC
RE
06/19MODERNA  : U.S. CDC Says Delivered 379,003,410 Doses Of Covid-19 Vaccine As Of J..
RE
06/19SINOVAC BIOTECH  : Singapore sees early rush for Sinovac vaccine
RE
More news
News in other languages on MODERNA, INC.
09:21aDPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 21.06.2021 - 15.15 Uhr
08:52aLes valeurs à suivre aujourd'hui à Wall Street - Lundi 21 juin 2021
08:46aMODERNA   : investit pour accroître sa production
08:08aMODERNA  : EY-Studie - Neue Virusvarianten befeuern Bedarf nach weiteren Impfsto..
07:18aSTUDIE : Corona-Krise schiebt Biotech-Branche an
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Stock Trading Strategies
MODERNA, INC. - 2020
The beginning of the move
BUY
More Stock Trading Analysis
Analysis
Samsung BioLogics shares ease after jumping on vaccine deal
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 168,87 $
Last Close Price 199,19 $
Spread / Highest target 23,5%
Spread / Average Target -15,2%
Spread / Lowest Target -58,3%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.90.67%79 980
LONZA GROUP LTD14.63%52 508
IQVIA HOLDINGS INC.33.76%45 934
CELLTRION, INC.-24.79%32 465
SEAGEN INC.-10.75%28 367
HANGZHOU TIGERMED CONSULTING CO., LTD14.49%24 102